Cyclerion Therapeutics, Inc. (CYCN) intrinsic value & 10-year financials
Cyclerion Therapeutics, Inc. (CYCN) has a Graham intrinsic value of $15.09 per share. At $3.36 on Oct 16, 2026, the stock trades 78% below that value. Over the last 9 fiscal years revenue shrank 12.1% a year to $2.1M, with an average return on invested capital of 461.9%.
- Graham intrinsic value
- $15.09
- Share price (Oct 16, 2026)
- $3.36
- Price vs Graham value
- 78% below
- Market cap
- $10.7M
- Revenue (FY2025)
- $2.1M
- Revenue growth (9-yr CAGR)
- -12.1%
- ROIC (10-yr avg)
- 461.9%
- Free cash flow (FY2025)
- —
CYCN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $2.1M | -$3.5M | -$1.11 | — | -239.8% | -55.5% |
| FY2024 | $2.0M | -$3.1M | -$1.21 | — | -181.4% | -36.0% |
| FY2023 | $0 | -$5.3M | -$2.25 | — | — | -2272.1% |
| FY2022 | $1.6M | $44.1M | -$1.01 | — | -2730.6% | 5394.8% |
| FY2021 | $3.9M | -$51.6M | -$1.32 | -$36.5M | -1400.2% | -243.6% |
| FY2020 | $2.3M | -$77.8M | — | -$74.0M | -3539.4% | -134.5% |
| FY2019 | $4.5M | -$123.0M | — | -$109.1M | -2774.3% | -170.5% |
| FY2018 | — | -$115.3M | — | -$100.9M | — | 1212.4% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cyclerion Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cyclerion Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -21.5% ROIC.
Cyclerion Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cyclerion Therapeutics, Inc. is modeled at -12.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $15.09 per share.